Feb 02, 2023 / 08:00PM GMT
Ron Cohen - Acorda Therapeutics, Inc. - President, CEO & Founder
Hello, everyone. Thanks for joining us for this update on Acorda Therapeutics. Before we begin, a reminder that the presentation will contain forward-looking statements, and I encourage you to consult our detailed filings with the SEC.
First, by way of introduction, I'm originally a Board-certified internist with strong background in neurology. I've been in the industry for 35 years and founded Acorda in 1995, with the mission that you see here that remains to this day. To develop therapies that will restore function and improve the lives of people with neurological diseases disabilities.
We have, so far, successfully developed and commercialized two important products. One, AMPYRA, is the only drug ever, to this day, approved to improve walking in people with multiple sclerosis. And the other is INBRIJA, an inhalable form of levodopa to treat OFF episodes for people with Parkinson's disease. And we'll talk some more about these in the coming slides.
So by way of introduction on how we're thinking about Acorda
Acorda Therapeutics Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers